JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schror, K.
Right arrow Articles by Darius, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schror, K.
Right arrow Articles by Darius, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia

K Schror, R Ohlendorf and H Darius

The potential therapeutic value of the chemically stable carbacyclin analog ZK 36 374 was studied in acute myocardial ischemia (MI). In anesthetized cats, the left anterior descending coronary artery was ligated and 30 min later an i.v. infusion of ZK 36 374 (0.18 microgram/kg X min) on vehicle was initiated and continued for 4.5 hr. ZK 36 374 reduced the ST-segment elevation at 2 to 5 hr (P less than .01) when compared to vehicle-treated MI cats. ZK 36 374 completely prevented the loss of CK specific activities and the decrease in percentage of bound cathepsin D in the infarcted area of the myocardium (P less than .01), but had no influences on any of these parameters in shamoperated animals. In addition, ZK 36 374 reversed the MI-induced decrease in circulating platelet count toward the preinfarction levels, probably by dispersion of circulating platelet aggregates. ZK 36 374 prevented the ischemia-induced loss of myocardial catecholamines from adrenergic nerve terminals. ZK 36 374, at 0.18 microgram/kg X min, exerted a maximum antiplatelet effect, whereas a significant decrease in arterial blood pressure was seen at 1.79 microgram/kg X min (-30- 40%). This indicates a considerable dissociation between antiplatelet and blood pressure-lowering activities of ZK 36 374 in this model. The data demonstrate a significant protective effect of ZK 36 374 in acute MI that might be associated with its platelet-stabilizing, antiadrenergic and myocardial cytoprotective activities.

Volume 219, Issue 1, pp. 243-249, 10/01/1981
Copyright © 1981 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
B. L. Robinson, T. Morita, K. Fujita, M. Chow, H. V. Schaff, and J. J. Morris
BYPASS CONDUIT VESSEL WALL BIOLOGY SUBSTANTIALLY INFLUENCES DOWNSTREAM MYOCARDIAL CONTRACTILE RESPONSE TO INJURY FROM ISCHEMIA AND REPERFUSION
J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 62 - 73.
[Abstract] [Full Text]

Home page
 ANGIOLOGYHome page
G. Brevetti, A. Rossini, S. Perna, A. Policicchio, T. Attisano, M. Ciotola, S. Quattrin, M. Condorelli, and M. Chiariello
Beneficial Effect of a New Prostacyclin Derivative on the Walking Capacity in Patients with Peripheral Arterial Insufficiency
Angiology, October 1, 1989; 40(10): 907 - 913.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics.